Welcome.
You’re here because you have been prescribed XELJANZ, a pill for adults with active psoriatic arthritis when 1 or more tumor necrosis factor (TNF) blocker medicines have been used, and did not work well or cannot be tolerated. XELJANZ for psoriatic arthritis is taken in combination with a nonbiologic disease-modifying antirheumatic drug (DMARD) such as methotrexate. XELJANZ+YOU is here to provide you information, tips, and tools to help you work with your doctor
on your treatment plan.
Your XELJANZ+YOU Welcome Kit is packed with information and tools that may help you.
XELJANZ+YOU WELCOME KIT
Click on the left and right arrows to explore the resources included in your XELJANZ+YOU Welcome Kit.
EASY-TO-OPEN WATER BOTTLE
This water bottle has been made specifically for people living with psoriatic arthritis joint pain, and swelling. Keep it filled so it's ready to use, and put it where it will remind you to take your medication.
WELCOME KIT BROCHURE
Get to know XELJANZ a little better with a closer look at how it works and how to incorporate it into your daily routine.
PsA JOURNAL
With this journal, you can write down your symptoms each day and share the results with your doctor.
CO-PAY SAVINGS PROGRAM
Our Co-Pay Savings Program may reduce out-of-pocket cost for eligible, commercially insured patients prescribed XELJANZ.
PROGRAM ORGANIZER
Keep the PsA Journal, brochures, and discussion guides in one place.
TRACKING YOUR SYMPTOMS
Recording your symptoms in the PsA Journal may be a useful tool to share with your doctor.
CO-PAY SAVINGS
Our Co-Pay Savings Program may reduce out-of-pocket cost for eligible, commercially insured patients prescribed XELJANZ.
FINANCIAL SUPPORT OPTIONS FOR ELIGIBLE PATIENTS
If you have a financial hardship and you've been prescribed XELJANZ, there may be programs available to help you.
YOUR DAILY ROUTINE
Learn how XELJANZ, when taken with a nonbiologic DMARD like methotrexate, may help treat your active psoriatic arthritis.
TELL US MORE
The information you provide here will be used by Pfizer and parties acting on its behalf to develop or improve materials related to certain chronic inflammatory conditions and use of XELJANZ.
